Aptevo Therapeutics Inc. - 100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naive Patients with Acute Myeloid Leukemia
Aptevo Therapeutics Inc. - 100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naive Patients with Acute Myeloid Leukemia
Dec 13, 2022
marketscreener.com
Aptevo Therapeutics: First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Aptevo Therapeutics: First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Nov 11, 2024
finanznachrichten.de
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
11 months ago
kron4.com
Aptevo Therapeutics' Bispecific Antibody Meets Trial Endpoints
Aptevo Therapeutics' Bispecific Antibody Meets Trial Endpoints
Nov 11, 2024
marketscreener.com
Aptevo Therapeutics: Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
Aptevo Therapeutics: Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
10 months ago
finanznachrichten.de
Aptevo Therapeutics Inc. annonce un taux de rémission de 100 % dans la cohorte 3 de l'essai RAINIER pour la LAM
Aptevo Therapeutics Inc. annonce un taux de rémission de 100 % dans la cohorte 3 de l'essai RAINIER pour la LAM
7 months ago
zonebourse.com
Aptevo Therapeutics: Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
Aptevo Therapeutics: Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
Nov 22, 2024
finanznachrichten.de
With New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech Movers
7 months ago
thestreet.com
Cognito Therapeutics raises $105m for Alzheimer’s therapeutic advancement
1 month ago
YahooRoss Law
0:35
Aptevo Therapeutics (Nasdaq: APVO) Reports 90% Remission* in AML Trial
1.4K views1 year ago
YouTubeRedChip Companies
2:53
Sorrento Therapeutics CEO talks moving Abivertinib into Phase 2 trial for Covid-19
Jul 21, 2020
CNBC
Solvonis Therapeutics CEO on name change, Awakn acquisition and 2025 priorities
Jan 14, 2025
proactiveinvestors.co.uk
ABEO: Momentum Building for Zevaskyn®
1 month ago
YahooZacks Small Cap Research
Novo Nordisk to acquire Akero Therapeutics for $4.7 billion — Akero stock jumps 20%, Novo Nordisk stock falls, here’s all about the deal
6 months ago
MSNPiyush Shukla
AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion
9 months ago
wsj.com
2:43
$APVO Stock Analysis: AML Study Sends Shares Soaring 78%+ 🔥📈
194 views7 months ago
YouTubeCNM
5:44
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Akero Therapeutics' CEO Andrew Cheng comments on today's 96 week MASH data and the future of efruxifermin.He describes the F4 patient population, and dicusses the efficacy… | BiotechTV
1 viewsJan 27, 2025
linkedin.com
3:10
$APVO Stock Analysis: No News Float Runner Breaks Out 🔥📈
101 views6 months ago
YouTubeCNM
2:25
APVO Stock Analysis (Aptevo Therapeutics Stock) September 16, 2025
118 views7 months ago
YouTubeMr Stockfather
2:48
APVO Stock Analysis (Aptevo Therapeutics Stock) September 18, 2025
209 views7 months ago
YouTubeMr Stockfather
0:31
Aptevo Therapeutics (NASDAQ: APVO): Advancing Bispecific Immunotherapies in Oncology
336 viewsDec 2, 2024
YouTubeRedChip Companies
3:00
APVO Stock Analysis (Aptevo Therapeutics Stock) December 27, 2025
38 views3 months ago
YouTubeFinance Podcast with Arman Nikoghosyan
9:49
Aptevo Therapeutics - Focus on Novel Immuno-Oncology Therapeutics
384 viewsJun 14, 2023
YouTubeHPR
4:47
Innovations in Biotech: Financial Reports and Cutting-Edge Treatments
3 weeks ago
YouTubeNewsRamp
0:42
APVO Stock (Aptevo Therapeutics stock analysis) APVO STOCK PREDICTION APVO STOCK analysis
1 week ago
YouTubeStratton Markets
12:02
Aptevo Therapeutics: Inside a Top-Tier Oncology Pipeline with COO Jeff Lamothe
17.4K views8 months ago
YouTubeRedChip Companies
1:09
APVO Stock ANALYSIS FRIDAY! (news crazy!) Aptevo Therapeutics
100 views11 months ago
YouTubemr. sicko Trading
12:48
Aptevo Therapeutics: My Insight on the SEPA & Stock Issuance
3 views2 months ago
YouTubeCorporate Decoder
27:00
RedChip Highlights Sixty Degrees Pharma (NASDAQ: SXTP) & Aptevo Therapeutics Inc. (NASDAQ: APVO)
3.2K views8 months ago
YouTubeRedChip Companies
19:06
Aptevo Therapeutics CEO Marvin L. White on the Future of Cancer Immunotherapy
2.9K viewsFeb 11, 2025
YouTubeRedChip Companies
See more